ESMO 2023: TROPION-Breast01 And -Lung01 Studies Breathe Life Into Dato-DXd
Executive Summary
The future for AstraZeneca/Daiichi Sankyo’s TROP2-targeted ADC candidate Dato-DXd is looking more positive after details of their TROPION-Lung01 and TROPION-Breast01 Phase III studies were presented at ESMO.